Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis
Status:
Completed
Trial end date:
2017-11-17
Target enrollment:
Participant gender:
Summary
We planned this study to investigate the efficacy and safety of XELOX (capecitabine and
oxaliplatin) plus lapatinib treatment in HER2-positive gastric cancer patients with liver
metastasis.